Comirnaty™ (Pfizer/BioNTech) is a vaccine that protects against COVID-19 disease caused by the SARS-CoV-2 virus.

How Comirnaty is made and what it contains

On this page you will find:

  • What type of vaccine is the Comirnaty vaccine is
  • How mRNA vaccine technology works
  • How the vaccine is made
  • What the vaccine contains

Visit page: How Comirnaty is made and what it contains.


How the vaccine works and the protection it provides

On this page you will find:

  • How mRNA vaccines, like Comirnaty, work
  • How protective is this vaccine?

Visit page: How the vaccine works and the protection it provides.


Comirnaty written resources:

Guidance supporting the administration of mRNA-CV vaccine

Comparison Chart - mRNA-CV (10 mcg) and mRNA-CV (30 mcg) version 7

Instructions for multi-dose vial Pfizer/BioNTech vaccine: preparation and administration

Expiry posters

Comirnaty FAQ section:

Please visit here for all frequently answered questions on the Cormirnaty vaccine.

Visit page: Comirnaty FAQ section


5 to 11 years old COVID resources

On this page, you will find resources for vaccinating 5 to 11-year-olds.

Visit page: 5 to 11 years old COVID resources


Medsafe Comirnaty age 5-11-year-olds (orange cap)             - 5 to 11-year-olds

Medsafe Comirnaty 12 years plus (purple cap) - 12 plus




  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
  • Thompson M, Burgess J, Naleway A, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep, 2021.
  • Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 2021.
  • Clancy, S. & Brown, W. (2008) Translation: DNA to mRNA to Protein. Nature Education 1(1):101
  • Comirnaty data sheet
  • Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2020;43(12):1205-10.
  • Law B, Sturkenboom M. D2. 3 Priority list of adverse events of special interest: COVID-19. The Brighton Collaboration.
  • Shimbabukuro T, CDC-COVID-19 Vaccine Task Force. COVID-19 vaccine safety update. March 2021. 2021 1 March 2021.Available from:
  • UK Health Security Agency. (2021). COVID-19 vaccine surveillance report Week 40. [last update 7 October 2021; cited 14 October 2021] Available from…
  • Nordström P, Ballin M, Nordström A. Association between risk of COVID-19 infection in nonimmune individuals and COVID-19 immunity in their family members. JAMA Internal Medicine. 2021. doi: 10.1001/jamainternmed.2021.5814
Last updated: 03 October 2022